Skip to main content
Caplight Logo









Oxford Endovascular

Oxford Endovascular

Private
OxfordHealthcare & Life Scienceshttps://oxfordendovascular.com/

Last Round

Series A

Extension

May 20, 2024

Total Funding Raised

$27.41M

Company Overview

Oxford Endovascular is a biotechnology company that develops origami-inspired, laser-cut metal alloy medical devices for the treatment of brain aneurysms.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

endovascular deviceflow-diverter stentintracranial aneurysmbrain aneurysm treatmentneurovascular surgeryflow diversionminimally invasive surgeryneurointerventional deviceorigami engineeringmedical implantneurovascular stentstroke caremedtechinterventional neuroradiology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oxford Endovascular Comparables

Compare Oxford Endovascular with similar companies based on industry and business-model similarity.

Oxford Endovascular comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NeuroMedica, Inc.
85%
Evasc Neurovascular
84%
Perflow Medical
84%

Oxford Endovascular Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionMay 20, 2024
Series AApr 8, 2021
GrantNov 16, 2020
GrantJul 10, 2020
GrantJul 8, 2019
Seed
Jan 6, 2016

Oxford Endovascular Investors

Notable investors and investment history

Oxford Endovascular investors
InvestorRounds
Innovate UKGrant
European Commission (Horizon Europe)Grant
Oxford Science EnterprisesSeed, Series A
EIT HealthGrant
Perivoli InnovationsSeries A
Oxford Technology Investment FundSeries A
Vulpes Investment ManagementSeries A, Series A Extension

Oxford Endovascular Filings

Explore SEC and related filing metadata, where available.

Oxford Endovascular filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Oxford Endovascular's valuation, stock price, and market status.

Is Oxford Endovascular a public or private company?

Oxford Endovascular is a private company.

What is the current stock price of Oxford Endovascular?

Oxford Endovascular is a private company with no public stock price. No recent secondary market data is available.

How much is Oxford Endovascular worth (valuation)?

Valuation information for Oxford Endovascular is not publicly available.

Can I buy Oxford Endovascular stock?

Oxford Endovascular shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Oxford Endovascular's last funding round?

Oxford Endovascular's most recent funding round was Series A Extension on May 20, 2024.

Who are the main investors in Oxford Endovascular?

Key investors in Oxford Endovascular include Vulpes Investment Management, Parkwalk Advisors.

Will Oxford Endovascular IPO soon?

No public IPO plans have been announced for Oxford Endovascular.

How can I track Oxford Endovascular secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Oxford Endovascular's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOxford
Employee Range10
Year Founded2015
Last FundingMay 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?